CAMBRIDGE, England, June 27,
2022 /CNW/ -- Abcam plc ("Abcam," "Company,"
"Group") (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply
of life science research tools, today announces the appointment of
Tommy Thomas as Vice President of
Tommy, who will be based in our Waltham, MA office, has over 20 years'
experience in the life sciences sector, largely focused in the area
of research tools. He joins Abcam from Avantor, where he was Vice
President, Investor Relations for several years. Prior to this he
was Vice President of Investor Relations, and then Chief Financial
Officer of Global Services at Perkin Elmer. Before joining Perkin
Elmer, Tommy spent eight years as a buy side analyst for TIAA-CREF
focused on the medical technology & life science tools
Michael Baldock, Chief
Financial Officer of Abcam, said: "I am delighted to have
Tommy joining us. His deep industry experience, significant
investor relations expertise, and strong institutional investor and
research analyst relationships are a major step forward for us.
Tommy will be a real asset to Abcam and our investors as we
continue to grow, differentiate ourselves in the marketplace, and
deliver value for all our stakeholders."
Tommy Thomas commented:
"I am very pleased to join Abcam at this important time in its
evolution. The Company's customer-centric model focusing on new
product innovation for researchers and clinicians in the life
sciences industry is highly differentiated. I look forward to
learning and telling our story as I build new friendships along the
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
antibodies, assays and other research tools to address important
targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health.
Abcam's worldwide customer base of approximately 750,000 life
science researchers uses Abcam's antibodies, reagents, biomarkers
and assays. By actively listening to and collaborating with these
researchers, the Company continuously advances its portfolio to
address their needs. A transparent programme of customer reviews
and datasheets, combined with an industry-leading validation
initiative, gives researchers increased confidence in their
Founded in 1998 and headquartered in Cambridge, UK, the
Company has served customers in more than 130 countries. Abcam's
ordinary shares are listed on the London Stock Exchange (AIM: ABC)
and its American Depositary Shares (ADSs) trade on the Nasdaq
Global Market (Nasdaq: ABCM).
Please visit corporate.abcam.com to find out more.
SOURCE Abcam plc